Print Page    E-mail Page    RSS    E-mail Alerts 

2017 Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
11/07/17
Bellerophon Provides Business Update and Reports Third Quarter 2017 Financial Results
WARREN, N.J., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today provided a business update and reported financial results for the third quarter ended September 30, 2017. “We continue to achieve important progress in all three of our INOpulse® clinical development programs,” said Fabian Tenenbaum, Chief Executive Officer of Bellerophon Therapeutics.  “In our INOvation-1 Phase 3 trial for Pulmonary Arterial Hyperten... 
09/27/17
Bellerophon Announces $23 Million Private Placement
Financing will support the continued development of the company’s INOpulse platform with Phase 3 clinical trials in Pulmonary Arterial Hypertension and Phase 2 trials in Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) and Pulmonary Hypertension associated with COPD WARREN, N.J., Sept. 27, 2017 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, announced today that it has entered into a definitive securities p... 
09/07/17
Bellerophon Therapeutics to Provide Corporate Update at Two Investor Conferences
WARREN, N.J., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced that Fabian Tenenbaum, President and Chief Executive Officer, will provide a corporate overview at the Rodman & Renshaw 19th Annual Global Investment Conference, and the Ladenburg Thalmann 3rd Annual Healthcare Conference. Rodman & Renshaw 19th Annual Global Investment Conference Date: Tuesday, September ... 
09/05/17
Bellerophon Announces Positive Top Line Phase 2 Data of INOpulse® for Treatment of Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease
Study Met its Primary and Secondary Endpoints Demonstrating Statistically Significant Improvements in Six-Minute Walking Distance, Hemodynamics and Blood Vessel Volume WARREN, N.J., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced positive top line data from a Phase 2 clinical trial evaluating INOpulse® in patients with Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease (PH-COPD... 
08/07/17
Bellerophon Reports Second Quarter 2017 Financial Results and Provides Business Update
WARREN, N.J., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today provided a business update and reported financial results for the second quarter ended June 30, 2017. “We continue to be encouraged with the progress of our Phase 3 clinical program in PAH, as well as Phase 2 programs in pulmonary hypertension associated with interstitial lung disease (PH-ILD) and chronic obstructive pulmonary disease (PH-COPD).  In o... 
08/03/17
Bellerophon Announces FDA Agreement on Phase 2b Study Design for INOpulse® in Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
Company to Host Key Opinion Leader Event on PH-ILD in New York City WARREN, N.J., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced agreement with the U.S. Food and Drug Administration (FDA) on the Phase 2 study design for INOpulse® in pulmonary hypertension associated with Interstitial Lung Disease (ILD).  The Company met with the FDA in June 2017 to present positive results from its recently completed... 
05/22/17
Positive Clinical Data on INOpulse® Presented at the American Thoracic Society 113th International Conference
Acute and Chronic Benefits Demonstrated with INOpulse in Patients with PH-IPF; Patients Achieved Statistically Significant Increases in Blood Vessel Volume; Consistent Improvements were Observed in Hemodynamics, 6MWD and Composite Endpoints of Oxygen Saturation and 6MWD Preliminary Results from an Ongoing Study in PH-COPD Support a Consistent Improvement in Vasodilation and Meaningful Reduction in Pulmonary Artery Pressures with 4 Weeks of INOpulse Treatment WARREN, N.J., May 22, 2017 (GLOBE... 
05/15/17
Bellerophon Reports First Quarter 2017 Financial Results and Provides Business Update
WARREN, N.J., May 15, 2017 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today provided a business update and reported financial results for the first quarter ended March 31, 2017. “Overall progress in our ongoing clinical programs has been encouraging and I am pleased with data recently reported in both PAH and in pulmonary hypertension associated with idiopathic pulmonary fibrosis (PH-IPF).  We look forward to the presentation o... 
05/10/17
Bellerophon Announces $3.0 Million Registered Direct Offering
WARREN, N.J., May 10, 2017 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced that it has entered into a definitive agreement with a single institutional investor for an offering of shares of its common stock with gross proceeds of $3.0 million in a registered direct offering. The closing of the offering is expected to take place on or about May 15, 2017, subject to the satisfaction of customary closing conditions. In ... 
05/01/17
Bellerophon to Present Positive Clinical Data on INOpulse® at the American Thoracic Society 113th International Conference
Data Show that INOpulse was Associated with Clinically Meaningful Improvements in Hemodynamics and Exercise Capacity in Difficult-to-Treat PH-IPF Patients Phase 2b Study in PH-IPF Population Planned WARREN, N.J., May 01, 2017 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced that it will present new clinical data from its Phase 2 study evaluating the use of INOpulse® in idiopathic pulmonary fibrosis patients with pulmo... 
04/07/17
Clinical Data on INOpulse® Presented at 37th Annual Meeting for the International Society for Heart and Lung Transplantation (ISHLT)
Clinical Data Presented From an Investigator Led Study of INOpulse in PAH Patients at Western University, London, Ontario and Allegheny General Hospital, Pittsburgh, PA Study Reinforces Hemodynamic Benefits of Pulsed iNO With Exercise WARREN, N.J., April 07, 2017 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today released clinical data from a poster presented at the 37th Annual Meeting for the International Society for Heart and ... 
03/27/17
Bellerophon Announces Poster Presentation on INOpulse® at 37th Annual Meeting for the International Society for Heart and Lung Transplantation
WARREN, N.J., March 27, 2017 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced a poster presentation at the 37th Annual Meeting for the International Society for Heart and Lung Transplantation (ISHLT) which will take place in San Diego, CA, from April 5 to 8.  The poster will feature data from an investigator-led study of INOpulse® in patients with pulmonary arterial hypertension (PAH). Title:   Ef... 
03/13/17
Bellerophon Reports Fourth Quarter 2016 Financial Results and Provides Business Update
WARREN, N.J., March 13, 2017 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2016. “I am pleased with the progress in our ongoing clinical programs to treat pulmonary hypertension in unmet or under-served chronic pulmonary disease areas,” stated Fabian Tenenbaum, Chief Executive Officer of Bellerophon Therapeutics. ... 
01/04/17
Bellerophon Therapeutics Announces FDA Acceptance of Modifications to INOpulse Pulmonary Arterial Hypertension Phase 3 Program
Protocol Changes have Potential to Reduce Time to Market for INOpulse by Approximately Two Years and Will Result in Substantial Cost Savings for Company WARREN, N.J., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced that it received confirmation from the U.S. Food and Drug Administration (FDA) of the Agency’s acceptance of all modifications proposed by the Company to its Phase 3 program for INOpulse in Pu...